Key facts
- DEEP’s last known valuation is $26.0M (Feb 2025).
- It has raised $6.2M; the latest was Seed Round ($3.9M) in Feb 2025.
- Notable investors include Innovestor, Lifeline Ventures, Johnson&Johnson Innovative Medicine.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for DEEP
- ·The full record, as it builds
Funding rounds
No funding rounds for DEEP are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DEEP
Operator of a digital platform designed to support the development and deployment of digital measures for clinical research. The company offers a device-agnostic model that defines and harmonizes measures across contexts of use, enabling pharmaceutical companies to streamline clinical development and drive the adoption of digital biomarkers across the healthcare ecosystem.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2022
- Employees
- 38
- Website
- deepmeasures.health/
- Ownership
- Privately Held (backing)
DEEP doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DEEP shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DEEP in its N-PORT filings yet. We sweep new filings monthly.